{"Clinical Trial ID": "NCT01073865", "Intervention": ["INTERVENTION 1:", "- Zoladex 10.8 mg", "ZOLADEX 10.8 mg (goserelin acetate): subcutaneous injection into the inside abdominal wall once every 12 weeks", "INTERVENTION 2:", "- Zoladex 3.6 mg", "ZOLADEX 3.6 mg (goserelin acetate): subcutaneous injection into the inside abdominal wall once every 4 weeks"], "Eligibility": ["Incorporation criteria:", "Premenopausal defined as 1) the last rules in the year following randomization, and 2) E2 10 pg/mL and FSH 30 mUI/mL within 4 weeks after randomization.", "\u2022 Sensitivity to hormone (ER positive) in primary or secondary tumour tissue.", "- Histological/cytological confirmation of breast cancer and are candidates for advanced breast cancer hormone therapy.", "- Exclusion criteria:", "Patients who have received tamoxifen or other hormonal treatments as adjuvant therapy for breast cancer within 24 weeks prior to randomisation and/or who have received hormone therapy for advanced breast cancer", "Patients who received LHRHa as adjuvant therapy for breast cancer within 48 weeks prior to randomisation", "Patients who relapsed during adjuvant hormonal treatment or within 48 weeks of the end of adjuvant hormonal treatment and/or"], "Results": ["Performance measures:", "Number of patients with progression-free survival (PFS) at 24 weeks", "A patient is considered to have survived without progression at week 24 if his or her PFS time is at least 24 weeks without a progression event before week 24 (i.e. the overall response to visits is a complete response (CR), a partial response (PR) or a stable disease (SD) during a tumour assessment at least 24 weeks after randomisation).", "Duration: 24 weeks after first administration", "Results 1:", "Title of the arm/group: Zoladex 10,8 mg", "Description of the arm/group: ZOLADEX 10.8 mg (goserelin acetate): subcutaneous injection into the inside abdominal wall once every 12 weeks", "Total number of participants analysed: 109", "Type of measure: Number of participants", "Unit of measure: Participants 67 61.5%", "Results 2:", "Title of the arm/group: Zoladex 3.6 mg", "Description of the arm/group: ZOLADEX 3.6 mg (goserelin acetate): subcutaneous injection into the inside abdominal wall once every 4 weeks", "Total number of participants analysed: 113", "Type of measure: Number of participants", "Unit of measure: Participants 68 60.2%"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/108 (3.70 per cent)", "ANEMIA 1/108 (0.93%)", "ENTEROCOLITIS 0/108 (0.00 %)", "PERIODOUNTAL DISEASE 0/108 (0.00 %)", "VOIX 0/108 (0.00 %)", "HIGH PEACE 1/108 (0.93%)", "- PNEUMONIA 0/108 (0.00 %)", "TETANUS 1/108 (0.93%)", "HYPERURICAEMIA 0/108 (0.00 %)", "DECLARED APPETITE 0/108 (0.00 %)", "MUSCULAR FAUNTURE 0/108 (0.00 %)", "THE PEACE IN EXTREMITY 1/108 (0.93%)", "DYSPNOEA 0/108 (0.00 %)", "Adverse Events 2:", "Total: 8/113 (7.08 per cent)", "ANEMIA 1/113 (0.88%)", "ENTEROCOLITIS 1/113 (0.88%)", "PERIODOUNTAL DISEASE 1/113 (0.88%)", "VOIX 1/113 (0.88%)", "- CHEST PAIN 0/113 (0.00 %)", "PNEUMONIA 1/113 (0.88%)", "TETANUS 0/113 (0.00 %)", "HYPERURICAEMIA 1/113 (0.88%)", "DECRESSED APPETITE 1/113 (0.88%)", "MUSCULAR FA\u00e7ON 1/113 (0.88%)", "THE PEACE IN EXTREMITY 0/113 (0.00 %)", "DYSPNOEA 3/113 (2.65 per cent)"]}